Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

EDIT - Editas Medicine, Inc. Financial Statements | Finranks

Home

/

EDIT

E

Editas Medicine, Inc. (EDIT)

NMS – Real Time Price. Currency in USD

2.85

-0.10 (-3.39%)

Market open: Aug 12, 2026, 1:57 PM EDT

2.94

-0.01 (-0.34%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Total Assets

Total Liabilities

Stockholders Equity

Total Debt

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

41M

32M

78M

20M

Cost of goods sold

-5M

-6M

-6M

-6M

Gross Profit

35M

27M

72M

13M

Operating expenses (excl. COGS)

-135M

-265M

-241M

-239M

Operating Income

-99M

-239M

-169M

-226M

Non-operating income, total

-61M

2M

16M

6M

Pretax income

-160M

-237M

-153M

-220M

Equity in earnings

0

0

0

0

Taxes

0

0

0

0

Non-controlling/minority interest

0

0

0

0

After tax other income/expense

0

0

0

0

Net income before discontinued operations

-160M

-237M

-153M

-220M

Discontinued operations

0

0

0

0

Net income

-160M

-237M

-153M

-220M

Dilution adjustment

0

0

0

0

Preferred dividends

0

0

0

0

Name

2025

2024

2023

2022

Total assets

187M-45.4%

342M-31.6%

499M-2.9%

514M

Total current assets

164M

289M

341M

357M

Total non-current assets

23M

52M

158M

158M

Total liabilities

159M-23.2%

207M+38.2%

150M-2.3%

154M

Total current liabilities

46M

77M

63M

60M

Total non-current liabilities

113M

130M

87M

94M

Total equity

27M

134M

349M

361M

Total liabilities & shareholders' equities

187M

342M

499M

514M

Total debt

77M+119.0%

35M-4.1%

37M-16.9%

44M

Name

2025

2024

2023

2022

Cash from operating activities

-165M

-210M

-132M

-177M

Cash from investing activities

139M

162M

-4M

114M

Cash from financing activities

40M

56M

118M

1M

Free cash flow

-166M+24.3%

-219M-60.1%

-137M+24.6%

-181M